Senzime Senzime
  • Home
  • Products
    • TetraGraph®
    • TetraSens
    • Data Management
    • Device Connectivity
    • Product Pipeline
  • The Need
  • Technology
    • Qualitative vs Quantitative Monitoring
    • EMG – New Gold Standard
  • Scientific
    • Key publications
    • Posters & Abstracts
    • Guidelines
  • Academy
    • Meet The Experts
    • Instructional Videos
  • About us
    • Mission & Vision
    • Board of Directors
    • Management
    • CEO Statement
    • Work@senzime
  • Order
    • Distributors
    • Order
    • Distributors – Login
  • Investor Relations
    • Press releases
    • Release Archive
    • News
    • Financial reports
    • Corporate governance
    • The share
    • Press Images
    • Calendar
    • Subscription
  • Contact
  • English
    • Swedish
    • American
Menu
    • Scientific
    • Key publications
    • Posters & Abstracts
    • Guidelines

Key Publications

Neuromuscular Transmission Monitoring

  • Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study
  • Consensus Statement on Perioperative Use of Neuromuscular Monitoring
  • Conceptual and technical insights into the basis of neuromuscular monitoring
  • The effects of Postoperative Residual Neuromuscular Blockade on hospital costs and intensive care unit admission: A population based cohort-study

Residual Neuromuscular Blockade

  • Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study
  • Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex
  • Current status of Neuromuscular Reversal and Monitoring: Challenges and Opportunities

Postoperative Pulmonary Complications

  • Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis

 

 

 

 

 

  • Are you interested?

  • Contact us for more information

Get contacted
About us
Senzime
  • Home
  • About us
  • Investor Relations
  • TetraGraph®
  • CliniSenz®
  • OnZurf®
  • Contact
  • info@senzime.com
  • +46 (0)18-51 56 40
    • Ulls väg 41 756 51 Uppsala, Sweden
  • Copyright 2021 Senzime
  • info@senzime.com
  • About Cookies
  • Privacy Policy
  • Created with by wasabiweb
  • CliniSenz, OnZurf, TetraGraph and TetraSens are trademarks owned by Senzime AB.